A phase 2 trial of Biogen and Ionis Pharmaceuticals’ tau-targeting candidate missed its primary endpoint. But while the ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that its partner, Biogen, shared compelling topline results from ...
Biogen (BIIB) added ~9% in the premarket on Thursday after the company shared results from a mid-stage trial evaluating diranersen, an experimental therapy for Alzheimer’s disease developed in ...
How Ionis Pharmaceuticals Stock Has Been Trading Ionis Pharmaceuticals (IONS) has drawn investor attention recently as the stock moved 2.3% in the latest session, with shorter term returns differing ...
Investor's Business Daily on MSN
Biogen is celebrating a first in Alzheimer's disease, but investors are leery
Biogen unveiled mixed results Thursday for its tau-targeting Alzheimer's treatment, leading the stock to drop.
--Ionis Pharmaceuticals, Inc. today reported financial results for the third quarter of 2024.. We are similarly well positioned for our second independent launch for donidalorsen, which we believe ...
An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced additional positive results from the pivotal study of zilganersen in children and adults living with Alexander disease (AxD), a rare, ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2026 virtual Annual Meeting of ...
Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals on Thursday won Food and Drug Administration approval of a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results